tiprankstipranks
Crinetics reports Q4 EPS (84c), consensus (82c)
The Fly

Crinetics reports Q4 EPS (84c), consensus (82c)

Reports Q4 revenue $709,000, consensus $250,000. "We continue to make great progress in our vision to build a premier, fully integrated endocrine company that can sustainably innovate pioneering therapies for our patients around the world," said Scott Struthers, founder and chief executive officer of Crinetics. "In 2022, we demonstrated pharmacologic proof-of-concept for CRN04894 and CRN04777, established global clinical study capabilities with our Phase 3 PATHFNDR program for paltusotine in acromegaly, and began laying groundwork for a potential commercial launch."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CRNX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles